Literature DB >> 8025996

Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.

H Yasue1, M Yoshimura, H Sumida, K Kikuta, K Kugiyama, M Jougasaki, H Ogawa, K Okumura, M Mukoyama, K Nakao.   

Abstract

BACKGROUND: B-type or brain natriuretic peptide (BNP) is a novel natriuretic peptide secreted from the heart that forms a peptide family with A-type or atrial natriuretic peptide (ANP), and its plasma level has been shown to be increased in patients with congestive heart failure. This study was designed to examine the sources and mechanisms of the secretion of BNP in comparison with those of ANP in control subjects and in patients with heart failure. METHODS AND
RESULTS: We measured the plasma levels of BNP as well as ANP in 16 patients with dilated cardiomyopathy (11 men and 5 women; mean age, 59 years) and 18 control subjects (9 men and 9 women; mean age, 54 years) by sampling blood from the femoral vein, the aortic root, the anterior interventricular vein (AIV), and the coronary sinus using the newly developed immunoradiometric assay systems. In the control subjects, there was no significant difference in the plasma ANP level between the aortic root and the AIV (24.0 +/- 5.2 pg/mL versus 32.2 +/- 17.0 pg/mL), but there was a highly significant step-up of the level between the AIV and the coronary sinus (32.2 +/- 17.0 pg/mL versus 371.4 +/- 111.1 pg/mL, P < .001). In contrast, there was a significant step-up of the plasma BNP level between the aortic root and the AIV (8.6 +/- 6.4 pg/mL versus 19.0 +/- 11.5 pg/mL, P < .01) but not between the AIV and the coronary sinus (19.0 +/- 11.5 pg/mL versus 28.8 +/- 14.0 pg/mL). On the other hand, in patients with dilated cardiomyopathy, there was a significant step-up in the plasma ANP level between the aortic root and the AIV (280.6 +/- 183.7 pg/mL versus 612.3 +/- 431.6 pg/mL, P < .01) and between the AIV and the coronary sinus (612.3 +/- 431.6 pg/mL versus 1229.0 +/- 772.7 pg/mL, P < .01). There was a significant step-up in the plasma BNP level between the aortic root and the AIV (268.4 +/- 293.2 pg/mL versus 511.6 +/- 458.1 pg/mL, P < .01) but not between the AIV and the coronary sinus (511.6 +/- 458.1 pg/mL versus 529.7 +/- 455.3 pg/mL) in patients with dilated cardiomyopathy. The arteriovenous difference at the AIV of the plasma level of BNP had a significant positive correlation with left ventricular end-systolic volume index (r = 0.859, P < .001) and a significant negative correlation with left ventricular ejection fraction (r = -.735, P < .001).
CONCLUSIONS: We conclude that (1) BNP is secreted mainly from the left ventricle in normal adult humans as well as in patients with left ventricular dysfunction, whereas ANP is secreted from atria in normal adult humans and also from the left ventricle in patients with left ventricular dysfunction; (2) secretion of BNP as well as ANP from the left ventricle increases in proportion to the severity of the left ventricular dysfunction, suggesting that the secretions of ANP and BNP from the left ventricle are regulated mainly by wall tension of the left ventricle; and (3) the peripheral plasma levels of ANP and BNP reflect the secretion rate of these hormones from the left ventricle and may be used as a marker of the degree of left ventricular dysfunction in patients with left ventricular dysfunction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8025996     DOI: 10.1161/01.cir.90.1.195

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  221 in total

Review 1.  Towards a blood test for heart failure: the potential use of circulating natriuretic peptides.

Authors:  S Talwar; P F Downie; L L Ng; I B Squire
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

2.  Relation of natriuretic peptide concentrations to central sleep apnea in patients with heart failure.

Authors:  Andrew D Calvin; Virend K Somers; Christelle van der Walt; Christopher G Scott; Lyle J Olson
Journal:  Chest       Date:  2011-06-02       Impact factor: 9.410

3.  The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure.

Authors:  Ahmet Fuat; Jeremy J Murphy; A Pali S Hungin; Jane Curry; Ali A Mehrzad; Andrew Hetherington; Jennifer I Johnston; W Stuart A Smellie; Victoria Duffy; Patricia Cawley
Journal:  Br J Gen Pract       Date:  2006-05       Impact factor: 5.386

Review 4.  Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides.

Authors:  R Senior; G Galasko; J V McMurray; J Mayet
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

5.  N-terminal pro-brain natriuretic peptide could be a marker of subclinical atherosclerosis in patients with type 2 diabetes.

Authors:  Takafumi Senmaru; Michiaki Fukui; Muhei Tanaka; Kazumi Sakabe; Emi Ushigome; Mai Asano; Masahiro Yamazaki; Goji Hasegawa; Naoto Nakamura
Journal:  Heart Vessels       Date:  2012-01-11       Impact factor: 2.037

6.  [Postoperative therapy using human atrial natriuretic peptide in cases of valve replacement].

Authors:  T Maeda; M Kitamura; A Kawai; M Hachida; S Aomi; M Endo; H Koyanagi; Y Sakomura; N Matsuda; H Kasanori
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-12

7.  Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.

Authors:  N C Davidson; W J Coutie; D J Webb; A D Struthers
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

Review 8.  The Japanese clinical practice guideline for acute kidney injury 2016.

Authors:  Kent Doi; Osamu Nishida; Takashi Shigematsu; Tomohito Sadahiro; Noritomo Itami; Kunitoshi Iseki; Yukio Yuzawa; Hirokazu Okada; Daisuke Koya; Hideyasu Kiyomoto; Yugo Shibagaki; Kenichi Matsuda; Akihiko Kato; Terumasa Hayashi; Tomonari Ogawa; Tatsuo Tsukamoto; Eisei Noiri; Shigeo Negi; Koichi Kamei; Hirotsugu Kitayama; Naoki Kashihara; Toshiki Moriyama; Yoshio Terada
Journal:  Clin Exp Nephrol       Date:  2018-10       Impact factor: 2.801

9.  Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.

Authors:  J H Henriksen; J P Gøtze; S Fuglsang; E Christensen; F Bendtsen; S Møller
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

10.  Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure.

Authors:  T Ishimitsu; T Nishikimi; Y Saito; K Kitamura; T Eto; K Kangawa; H Matsuo; T Omae; H Matsuoka
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.